Dudediligence.

Alkermes plc

ALKSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$378.1MSep ’24$430.0MDec ’24$306.5MMar ’25$390.7MJun ’25$394.2MSep ’25$384.5MDec ’25$392.9MMar ’26$496.0MJun ’26
Net income, by quarter
$92.4MSep ’24$146.5MDec ’24$22.5MMar ’25$87.1MJun ’25$82.8MSep ’25$49.4MDec ’25−$66.5MMar ’26$501,000Jun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$1.17B$1.11B$1.66B$1.56B$1.48B
Gross profit$976.4M$893.7M$1.41B$1.31B$1.28B
Operating income$97.7M−$6.1M$414.1M$420.6M$254.0M
Net income−$48.2M−$158.3M$355.8M$367.1M$241.7M
Operating cash flow$101.7M$21.0M$401.4M$439.1M$520.8M
Free cash flow$73.7M−$17.2M$353.3M$405.6M$480.3M
Cash$337.5M$292.5M$457.5M$291.1M$388.6M
Debt$295.8M$293.3M$290.7Mnone on file$0.00
Shares outstanding161.9M164.4M167.0M162.2M165.6M